局部区域晚期鼻咽癌患者辅助化疗:3期多中心随机对照试验的长期结果
本3期多中心随机对照试验在中国7家机构纳入III-IVB期(除T3-4N0)鼻咽癌患者,随机接受同步放化疗联合辅助化疗或单纯同步放化疗。中位随访68.4个月,5年无失败生存率联合组75% vs 单纯组71%(HR 0.88,95%CI 0.64-1.22;P=0.45),晚期3-4级毒性两组无显著差异(P=0.14)。
要点
- 同步放化疗后加辅助顺铂+氟尿嘧啶未显著改善长期无失败生存(HR 0.88,95%CI 0.64-1.22;P=0.45)。
- 5年无失败生存率联合组75% vs 单纯组71%。
- 晚期3-4级毒性联合组27% vs 单纯组21%(P=0.14),无显著增加。
核心结论
- 基于长期随访数据,局部区域晚期鼻咽癌同步放化疗后加辅助顺铂和氟尿嘧啶仍未显示显著生存获益,且未显著增加晚期毒性。
研究设计与样本
- 3期多中心随机对照试验,在中国7家机构纳入III-IVB期(除T3-4N0)鼻咽癌患者,随机分为同步放化疗联合辅助化疗组(251例)和单纯同步放化疗组(257例)。
- 两组均接受顺铂40 mg/m2每周一次,同步放疗最多7周;联合组后续接受辅助顺铂80 mg/m2和氟尿嘧啶800 mg/m2/d持续120小时,每4周一次,共3周期。
- 主要终点为无失败生存。
主要发现
- 中位随访68.4个月,估计5年无失败生存率联合组75% vs 单纯组71%(HR 0.88,95%CI 0.64-1.22;P=0.45)。
- 联合组249例中66例(27%)与单纯组254例中53例(21%)发生一个或多个晚期3-4级毒性(P=0.14)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM OF THE STUDY: Previous results from our trial showed that adjuvant cisplatin and fluorouracil chemotherapy did not significantly improve survival after concurrent chemoradiotherapy (CCRT) in locoregionally advanced nasopharyngeal carcinoma (NPC) at 2 years. Here, we present the data of long-term survival and late toxicities to further assess the ultimate therapeutic index of adjuvant chemotherapy (AC). METHODS: Patients with stage III-IVB (except T3-4N0) NPC were randomly assigned to receive CCRT plus AC or CCRT only at seven institutions in China. Patients in both groups received cisplatin 40 mg/m2 weekly up to 7 weeks concurrently with radiotherapy. The CCRT plus AC group subsequently received adjuvant cisplatin 80 mg/m2 and fluorouracil 800 mg/m2/d for 120 h every 4 weeks for three cycles. The primary end-point was failure-free survival. RESULTS: Two hundred and fifty-one patients were randomised to the CCRT plus AC group and 257 to the CCRT only group. After a median follow-up of 68.4 months, estimated 5-year failure-free survival rate was 75% in the CCRT plus AC group and 71% in the CCRT only group (hazard ratio 0.88, 95% confidence interval 0.64-1.22; p = 0.45). 66 (27%) of 249 patients in the CCRT plus AC group and 53 (21%) of 254 patients in the CCRT only group developed one or more late grade 3-4 toxicities (p = 0.14). CONCLUSION: Adjuvant cisplatin and fluorouracil chemotherapy still failed to demonstrate significant survival benefit after CCRT in locoregionally advanced NPC based on the long-term follow-up data, and addition of adjuvant cisplatin and fluorouracil did not significantly increase late toxicities. REGISTRATION NUMBER: NCT00677118.
引用
- Chen L, Hu CS, Chen XZ, et al. Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trial. Eur J Cancer. 2017. PMID: 28235726. doi:10.1016/j.ejca.2017.01.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。